Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2019, 28(4):158-167

Patient management after myocardial infarction

Kmec J1, Studenčan J1, Kmec M2
1 Kardiocentrum FNsP J.A. Reimana Prešov, Fakulta zdravotníckych odborov Prešovská univerzita v Prešove
2 Interného oddelenia FNsP J. A. Reimana Prešov, Slovenská republika

The in-hospital mortality of unselected patients with STEMI in the national registries of the ESC countries varies between 4 - 12%. Key lifestyle interventions include cessation of smoking, optimal blood pressure control, diet advice and weight control, and encouraging physical activity. Europe and US guidelines for optimizing post-MI drug therapy recommend intensive hypolipidemic therapy, ACE inhibitors/ARB, antithrombotic therapy and beta-blockers. Low treatment adherence is an important barrier to achieving optimal treatment targets and is associated with worse outcomes. A suitable strategy to reduce the lack of adherence is to use fixed combinations or the polypill. Fig. 5, Ref. 31, on-line full text (Free, PDF) www. cardiologyletters.sk

Keywords: myocardial infarction; hypolipidemics; ACE inhibitors; beta-blockers; polypill

Published: April 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kmec J, Studenčan J, Kmec M. Patient management after myocardial infarction. Cardiology Letters. 2019;28(4-5):158-167.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nichols M, Townsend N, Scarborough P, et al. European cardiovascular disease statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis 2012.
    2. Camm AJ, Lüscher TF, Maurer G, et al. The ESC Textbook of Cardiovascular Medicine. Oxford University Press; 2018: tlaku, úprava stravovania, kontrola a prípadne úprava telesnej hmotnosti a väčšia fyzická aktivita. U pacientov so STEMI s indikáciou k primárnej PKI sa odporúča podávať DAPT (ASA + DAPT - inhibítor P2Y12 (prasugrel, tikagrelor alebo klopidogrel)) počas až 12 mesiacov. U pacientov s vyšším hemoragickým rizikom je vhodné duálnu liečbu skrátiť a u vybraných pacientov s nízkym rizikom krvácania a vysokým rizikom ischemických komplikácií možno naopak zvážiť predĺženie DAPT. Napriek nejednoznačným výsledkom RKŠ a metaanalýz sa odporúča zvážiť rutinné užívanie BB u všetkých pacientov so DOI:10.1093/med/9780198784906.001.0001. Go to original source...
    3. Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe 2014: Epidemiological update. Eur Heart J 2014;35:2950-2959. Go to original source...
    4. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J2018;39:119-177. doi:10.1093/eurheartj/ehx393. Go to original source...
    5. Studenčan M, Hricák V, Kovář F, et al. Manažment akútnych koronárnych syndrómov na Slovensku v roku 2015. Aktuálne analýzy registra SLOVAKS. Cardiology Lett. 2017;26:125-137.
    6. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs challenges for research and for patient care. J Am Coll Cardiol 2015;66:1273-1285. Go to original source...
    7. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapidrisk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009;119:1873-1882. Go to original source...
    8. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dualantiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for CardioThoracic Surgery (EACTS). Eur Heart J2018; 39:213-260. Go to original source...
    9. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J2019;40:87-165. Go to original source...
    10. Pedretti RFE. Beta-blockers after myocardial infarction: Are they useful to all patients? And how long should be the beta-blocker therapy? Monaldi Archives for Chest Disease 2018;88:971. Go to original source...
    11. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;3:267-315. Go to original source...
    12. Huang BT, Huang FY, Zuo ZL, et al. Meta-analysis of relation between oral β-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol 2015;115:1529-1538. Go to original source...
    13. de Kam PJ, Voors AA, Fici F, et al. The revised role of ACEinhibition after myocardial infarction in the thrombolytic/ primary PCI era. JRAAS 2004;5:161-168. Go to original source...
    14. Fox KM. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788. Go to original source...
    15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. Go to original source...
    16. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. Go to original source...
    17. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. Go to original source...
    18. Lofman I, Szummer K, Olsson H, et al. Association between mineralocorticoid receptor antagonist use and outcome in myocardial infarction patients with heart failure. J Am Heart Assoc. 2018;7:e009359. DOI: 10.1161/JAHA.118.009359. Go to original source...
    19. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405-1410. Go to original source...
    20. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-1718. Go to original source...
    21. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-1316. Go to original source...
    22. Dohi T, Miyauchi K, Okazaki S, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis 2010;210:497-502. Go to original source...
    23. Fujisue K, Tsujita K. Current status of lipid management in acute coronary syndrome. Journal of Cardiology 2017;70:101-106. Go to original source...
    24. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-2397. Go to original source...
    25. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-1722. DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>. Go to original source...
    26. Steg PG, Schwartz GG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097-2107.DOI: 10.1056/NEJMoa1801174. Go to original source...
    27. Fábryová Ľ. Otvorené otázky z kardiovaskulárnych štúdiî FOURIER a ODYSSEY Outcomes. AtheroRev 2018;3:209-212.
    28. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal 2016;37:2999-3058. doi:10.1093/eurheartj/ehw272. Go to original source...
    29. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125:882-887. Go to original source...
    30. Huber CA, Meyer MR, Steffel J, et al. Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population. Clinical Therapeutics 2019;41:107-117. Go to original source...
    31. Lutai MI, Golikova IP. The effectiveness of treatment of patients with stable coronary heart disease and concomitant arterial hypertension: the results of a multicenter study Prestol. Ukrainian Cardiology Magazine 2019;26:13-24. Go to original source...

    Return to the content